Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.33 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | AGXT | P21549 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14511260 | 0.92 | MEN1 (0.41) | MEN1KMT2ASLC5A1SLC5A2GLA | |
| SCHEMBL132660 | 0.92 | MEN1 (0.41) | MEN1KMT2ASLC5A1SLC5A2GLA | |
| SCHEMBL14511264 | 0.90 | MEN1 (0.35) | MEN1KMT2ACA1CA2GLA | |
| SCHEMBL1059672 | 0.87 | ALDH1A1 (0.37) | MEN1KMT2AIDO1KDM4E | |
| SCHEMBL19221818 | 0.87 | ALDH1A1 (0.37) | MEN1KMT2AIDO1KDM4E | |
| SCHEMBL24371819 | 0.87 | ALDH1A1 (0.37) | MEN1KMT2AIDO1KDM4E | |
| SCHEMBL18999217 | 0.87 | ALDH1A1 (0.37) | MEN1KMT2AIDO1KDM4E | |
| SCHEMBL21063154 | 0.87 | ALDH1A1 (0.37) | MEN1KMT2AIDO1KDM4E | |
| SCHEMBL13382976 | 0.87 | ALDH1A1 (0.37) | MEN1KMT2AIDO1KDM4E | |
| SCHEMBL24498686 | 0.87 | ALDH1A1 (0.37) | MEN1KMT2AIDO1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464106-B2 | Oligonucleotides useful for detecting and analyzing nucleic acids of interest | EXIQON A/S (DK) | 2016-10-11 | — | — | US | disclosed |
| US-20120157333-A1 | OLIGONUCLEOTIDES USEFUL FOR DETECTING AND ANALYZING NUCLEIC ACIDS OF INTEREST | EXIQON A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| EP-1446412-B1 | NOVEL LNA COMPOSITIONS AND USES THEREOF | EXIQON AS (DK) | 2012-03-07 | — | — | EP | disclosed |
| US-20070117144-A1 | Oligonucleotides useful for detecting and analyzing nucleic acids of interest | EXIQON A/S (DK) | 2007-05-24 | — | — | US | disclosed |
| EP-1446412-A2 | NOVEL LNA COMPOSITIONS AND USES THEREOF | Exiqon A/S (DK) | 2004-08-18 | — | — | EP | disclosed |
| US-20030224377-A1 | Novel LNA compositions and uses thereof | QIAGEN GMBH (DE) | 2003-12-04 | — | — | US | disclosed |
| WO-2003020739-A2 | NOVEL LNA COMPOSITIONS AND USES THEREOF | EXIQON A/S (DK) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030224377-A1 | Novel LNA compositions and uses thereof | RNGTT, NCL, NSUN2 | MEN1 1124/4885KMT2A 1689/4885CA1 3328/4885 |
| US-20120157333-A1 | OLIGONUCLEOTIDES USEFUL FOR DETECTING AND ANALYZING NUCLEIC ACIDS OF INTEREST | UPF1, DCLRE1B, SNRPA1 | MEN1 2069/4885KMT2A 2665/4885CA1 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.